drugset

drugset / Trial / NCT00344786

Phase 1, Dose-Escalation Study of Oral CNF2024(BIIB021) in CLL

NCT00344786 ↗

Phase 1 Terminated 15 enrolled Biogen

Non-randomizedSingle-groupOpen-labelTreatment

Summary

CLL dosing escalating study; daily dosing schedule; PK/PD safety

Timeline

Start: 2006-02
Primary completion: 2008-07
Completion: 2008-09

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	BIIB021	Small molecule	12.5 mg	Oral

Indications